NCT05729711Active, not recruiting
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
TEZSPIRE Subcutaneous Injection 210mg Specific Use-results Study (Long Term) in Patients With Bronchial Asthma.
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. 1. Development of related AEs 2. Contributing factors possibly having an impact on the safety and effectiveness 3. Development of unexpected related AEs
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 416 (actual)
- First submitted
- 7 Feb 2023
- Start date
- 4 Apr 2023
- Primary completion date
- 16 Nov 2029
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma
- NCT number
- NCT05729711
What you commit to
- Study type: Observational
- Participants enrolled: 416
- From 4 Apr 2023 to the primary completion date, 16 Nov 2029
- 33 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- The evaluable patients are those treated with Tezspire for the first time due to "Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy)
Sex: All · Does not accept healthy volunteers
Sites (33)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.